Abzena
Abzena is a privately held, end-to-end biologics and bioconjugate CDMO+CRO providing integrated services from antibody discovery through cGMP manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins for biotech and pharmaceutical clients across the US and Europe.
- Company typePrivate
- Founded2004
- HeadquartersSan Diego, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Abzena does
Abzena is a privately held, end-to-end contract development and manufacturing organization (CDMO) plus contract research organization (CRO) specializing in complex biologics and bioconjugates. Founded in 2004 and owned by private equity firm Welsh, Carson, Anderson & Stowe, Abzena operates integrated facilities in San Diego, California (single-use cGMP biologics manufacturing, bioreactors up to 2,000L), Bristol, Pennsylvania (high-potency bioconjugation and ADC manufacturing), and Cambridge, United Kingdom (headquarters and primary R&D site at Babraham Research Campus), with a planned North Carolina GMP facility announced in conjunction with a March 2022 $65M growth round.
The company's product offering sits across two layers. The proprietary technology layer includes ThioBridge® (a site-specific ADC/AOC conjugation platform producing stable, homogeneous conjugates with controlled drug-to-antibody ratio, with two licensee candidates currently in the clinic), AbZelectPRO™ and its new AbZelectPRO™-KO and AbZelectPRO™-KO+ GS knockout cell line variants (delivering titers up to 10 g/L via Revvity's CHOSOURCE™ and ProteoNic's 2G UNic® integrations), EpiScreen® 2.0 immunogenicity testing, LabZient™ analytical data platform, Composite Human Antibody™ humanization, and Composite Proteins™ deimmunization. The service layer spans antibody discovery, antibody engineering, developability assessment, analytics and bioassays, formulation development, upstream and downstream process development, cGMP clinical through commercial manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins, plus regulatory affairs support across FDA and EMA. The company reports 1,400+ lead candidates designed, 100+ production cell lines developed, 2,000+ bioconjugates developed, 400+ ADCs produced, and 70+ integrated DNA-to-IND programs delivered.
Abzena earns revenue through three streams: fee-for-service CRO contracts (typically 12–36 month milestones), CDMO manufacturing billed per batch or campaign under long-term supply agreements, and technology licensing of proprietary platforms and antibodies (exemplified by the October 2025 exclusive commercial license of an internal mAb to Orion). Pricing is program-specific and not publicly disclosed, although AbZelectPRO™ is marketed with transparent pricing-to-IND and no royalty fees. Customer segments are horizontally oriented — emerging and established biotech and biopharma developers requiring integrated discovery, development, and manufacturing support for complex modalities — distributed across North America, Europe, and Asia-Pacific via dedicated BD professionals in each region. Repeat-client rates are described as high, with the "grow-with-the-client" strategy converting early-stage CRO programs into late-stage manufacturing supply.
Abzena firmographics
Firmographics- Name
- Abzena
- Legal name
- Abzena
- Website
- https://abzena.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Abzena is a privately held, end-to-end biologics and bioconjugate CDMO+CRO providing integrated services from antibody discovery through cGMP manufacturing of monoclonal antibodies, ADCs, AOCs, RDCs, bispecifics, and fusion proteins for biotech and pharmaceutical clients across the US and Europe.
- Ownership category
- akta.pro rank
Abzena industry classification
Industry- Product category
- Biologics and Bioconjugate CDMO/CRO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Abzena is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Abzena business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Contract Research & Development Services (CRO): Abzena provides fee-for-service contract research across discovery, antibody engineering, developability assessment, analytics, bioassays, immunogenicity testing, cell line development, and process development. Revenue is earned through milestone-based project contracts typically spanning 12–36 months for integrated programs.
- Contract Manufacturing Services (CDMO): GMP clinical through commercial manufacturing of biologics and bioconjugates, including ADCs. Revenue generated through manufacturing campaigns, typically billed per batch or campaign with long-term supply agreements. Facilities in San Diego, Bristol, and Cambridge support multi-regional manufacturing.
- Technology Licensing: Abzena licenses its proprietary platforms (ThioBridge®, AbZelectPRO™, Composite Human Antibody™, etc.) and grants exclusive commercial licenses for developed antibodies. Orion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, supporting Orion's oncology R&D pipeline.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Abzena product offering
Product offeringCore offering
Abzena is a fully integrated biologics and bioconjugate CDMO+CRO providing end-to-end services from antibody discovery through cGMP commercial manufacturing. Its core service portfolio spans antibody discovery, engineering, developability assessment, analytics and bioassays, immunogenicity testing, mammalian cell line development, process development, formulation, bioconjugation (ADCs, AOCs, RDCs), and clinical-to-commercial cGMP manufacturing, supported by proprietary platforms including ThioBridge®, AbZelectPRO™, EpiScreen® 2.0, LabZient™, Composite Human Antibody™, and Composite Proteins™.
Product overview
Abzena operates as a fully integrated biologics and bioconjugates CDMO + CRO, offering end-to-end services from antibody discovery through commercial manufacturing. The company provides a comprehensive platform of proprietary technologies including ThioBridge® for site-specific ADC/AOC conjugation, AbZelectPRO™ family of cell line development platforms (AbZelectPRO™, AbZelectPRO™-KO, AbZelectPRO™-KO+), EpiScreen® 2.0 for immunogenicity testing, LabZient™ for rapid analytical data, Composite Human Antibody™ for humanization, and Composite Proteins™ for deimmunization. These technology platforms are complemented by integrated CRO/CDMO services spanning antibody discovery, engineering, developability assessment, analytics and bioassays, cell line development, process development, formulation development, and cGMP clinical through commercial manufacturing. The company specializes in complex biologics including monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radionuclide-drug conjugates (RDCs), bispecifics, and fusion proteins, with facilities in San Diego, CA, Bristol, PA, and Cambridge, UK.
Differentiator
Problem solved
Functional benefit
Brands
- ThioBridge®: Proprietary site-specific conjugation technology for improved ADC design and delivery
- AbZelectPRO™
- EpiScreen® 2.0
- LabZient™
- Composite Human Antibody™
- Composite Proteins™
Products and services
- ThioBridge® Conjugation Platform Site-specific bioconjugation platform for ADC and AOC development, producing stable, homogeneous conjugates with precise drug-to-antibody ratio (DAR), re-bridging across disulfide bonds to create stable, scalable, high-yield conjugates for biotech and pharmaceutical developers of next-generation therapeutics.
- AbZelectPRO™ Cell Line Development Platform GMP-ready, high-yielding mammalian cell line development platform using CHO-K1 expression systems with ProteoNic's 2G UNic® vector technology, enabling stable pools in 3 weeks, RCB in 10 weeks, and GMP in 6 months for biologic developers.
- AbZelectPRO™-KO GS Knockout Cell Line Platform Next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression system integrated with CHOSOURCE™ cell lines for enhanced productivity and flexibility in therapeutic antibody production, available as standalone CLD or fully integrated GMP program.
- AbZelectPRO™-KO+ ADCC+ Cell Line Platform Advanced GS knockout ADCC+ cell line platform (double knockout of GS and fucosyltransferase genes) for afucosylated proteins with enhanced antibody-dependent cellular cytotoxicity, available as standalone CLD or fully integrated GMP program.
- EpiScreen® 2.0 Immunogenicity Testing Platform Advanced immunogenicity risk assessment platform utilizing assays to evaluate T cell epitopes and mitigate immunogenicity risks for biologic developers.
- LabZient™ Analytical Data Platform Rapid analytical data platform that streamlines and de-risks the path to IND applications for antibodies and biologics, enhancing operational efficiencies for biologic developers.
- Antibody Discovery Services High-affinity antibody discovery services including hybridoma sequencing for identifying lead candidates, serving biotech and pharmaceutical companies developing therapeutic antibodies.
- Antibody Engineering Services Antibody design, protein engineering, humanization, and deimmunization services for optimizing antibody properties, leveraging Composite Human Antibody™ and Composite Proteins™ platforms.
- Mammalian Cell Line Development Services GMP-ready mammalian cell line development services using CHO-K1 expression systems, accelerating timelines and ensuring scalability for biologics developers.
- cGMP Biologics Manufacturing Clinical through commercial cGMP manufacturing of biologics (mAbs, fusion proteins, bispecifics) with facilities in San Diego, CA and Bristol, PA, including technology transfer, scale-up, and quality systems per ICH guidelines.
- Bioconjugate Services (ADCs, AOCs, RDCs) Specialized bioconjugation services including linker-payload design, ADC/AOC/RDC development, complex chemistry, and GMP manufacturing for ADC, antibody-oligonucleotide conjugate, and radionuclide-drug conjugate developers.
- DNA-to-IND/CTA Integrated Program Integrated accelerated pathway from DNA sequence to IND submission combining cell line development, process development, formulation, analytical methods, GMP manufacturing, and regulatory support under a single program for biotech and pharma developers.
Quantifiable outcome
- Stable pools generated in 3 weeks, RCB in 10 weeks, GMP-ready in 6 months via AbZelectPRO™
- +5 more outcomes
Companies that use Abzena
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Abzena technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Abzena partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- MabqicoreStrategic partnership to offer an integrated drug discovery and development solution, combining Mabqi's antibody discovery technology with Abzena's development and manufacturing capabilities. The collaboration leverages Mabqi's LiteMab platform and Abzena's extensive biologics services to support a broad range of modalities including monoclonal antibodies and bioconjugates, aiming to streamline and accelerate biopharma drug development.
- Orion CorporationcoreOrion obtained an exclusive commercial license for one of Abzena's monoclonal antibodies targeting a high unmet need cancer, to be used in Orion's oncology R&D pipeline. The antibody was developed at Abzena's UK facility using proprietary technology and manufacturing platforms. This collaboration supports Orion's oncology treatment development with Abzena providing ongoing manufacturing support from UK and US facilities.
- Revvity (CHOSOURCE™)coreRevvity licensed its proprietary CHOSOURCE™ Glutamine Synthetase (GS) knockout CHO-K1 cell lines to Abzena for integration into the AbZelectPRO™ CLD platform. CHOSOURCE™ is an industry-standard, cGMP-manufactured cell line referenced in 90+ IND filings and 4 approved drugs. The ADCC+ double knockout variant was also licensed. This partnership enables Abzena's GS knockout CLD offerings (AbZelectPRO™-KO and AbZelectPRO™-KO+).
- ProteoNic (2G UNic®)coreProteoNic's 2G UNic® next-generation vector technology is integrated into the AbZelectPRO™ CLD workflow, paired with Revvity's CHOSOURCE™ GS knockout cell lines. The technology boosts productivity in CHOSOURCE™ and other cell lines, enhancing Abzena's cell line development platform performance and enabling high-titer expression of up to 10g/L.
- Argonaut Manufacturing Services Inc.minorAbzena's collaboration with Argonaut Manufacturing Services Inc. was noted in the June 2024 strategic transactions in the biopharmaceutical CMO/CRO sector. Nature of collaboration relates to supply chain resilience and expanded service capabilities for biopharma customers.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Abzena competitors and assessment
Company assessmentDirect peers
- Piramal Pharma Solutions: Contract development and manufacturing organization with dedicated ADC and bioconjugate capabilities through its Grangemouth, UK site (acquired from Coldstream). Overlaps with Abzena in ADC linker-payload synthesis and bioconjugation services, with a similar UK heritage.
- AGC Biologics: Mid-to-large scale biologics CDMO offering mammalian and microbial-based therapeutic protein and bioconjugate manufacturing, including clinical and commercial GMP capacity. Most similar in scale and modality mix to Abzena among publicly tracked CDMOs.
- Bionova Scientific: Specialized bioconjugate and ADC-focused CDMO offering analytical, process development, and GMP manufacturing services. Direct comparator to Abzena for bioconjugate-focused clients with shared modality focus on ADCs and related conjugates.
Broad incumbents
- FUJIFILM Diosynth Biotechnologies: Global biologics CDMO with extensive mammalian cell culture and microbial fermentation capabilities, plus a growing bioconjugate franchise. Comparable to Abzena in serving complex biologics developers across modalities including ADCs and bispecifics.
- Samsung Biologics: Large-scale biologics CDMO with multiple GMP plants offering end-to-end services from cell line development to commercial manufacturing. John Gill, Abzena's VP of CLD, previously worked at Samsung Biologics, indicating direct competitive overlap.
- Catalent (now part of Novo Holdings): Global CDMO with significant biologics and bioconjugate capabilities, including the SMARTag site-specific ADC platform that directly competes with ThioBridge®. Overlaps with Abzena in ADC development, cell line services, and integrated biologics manufacturing.
- Lonza Biologics: One of the largest global biologics CDMOs operating across mammalian and microbial manufacturing, ADC payload-linker synthesis, and integrated drug substance/product services. Comparable to Abzena across biologics and bioconjugate CDMO offerings but at significantly larger scale.
- Thermo Fisher Scientific (Patheon / Brammer Bio): Global CDMO with significant biologics capabilities via the Brammer Bio acquisition, providing cell line, process development, and GMP manufacturing for mAbs and ADCs. Comparable to Abzena across integrated biologics services.
- WuXi Biologics: One of the largest biologics CDMOs globally, offering cell line development, process development, and GMP manufacturing for mAbs, bispecifics, and ADCs. Compares to Abzena in integrated DNA-to-IND services and ADC manufacturing scale.
Emerging players
- Heidelberg Pharma: Biotechnology company with proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform and CDMO arm, focused on novel payloads and bioconjugation technologies. Comparable to Abzena at the conjugation technology level rather than full-service CDMO scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Abzena social profiles
Digital presenceAbzena financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abzena leadership team
Management profileNumber of profiles
Profiles7 records
Abzena funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abzena M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abzena
What does Abzena do?
Abzena is a fully integrated biologics and bioconjugate CDMO+CRO providing end-to-end services from antibody discovery through cGMP commercial manufacturing. Its core service portfolio spans antibody discovery, engineering, developability assessment, analytics and bioassays, immunogenicity testing, mammalian cell line development, process development, formulation, bioconjugation (ADCs, AOCs, RDCs), and clinical-to-commercial cGMP manufacturing, supported by proprietary platforms including ThioBridge®, AbZelectPRO™, EpiScreen® 2.0, LabZient™, Composite Human Antibody™, and Composite Proteins™.
Is Abzena a public or private company?
Abzena is a private company. It is classified as private equity controlled and is currently operating.
When was Abzena founded?
Abzena was founded in 2004. It employs 501 to 1,000 people.
Where is Abzena based?
Abzena is headquartered in San Diego, United States, in the North America region.
How does Abzena make money?
Three revenue lines are on record. Contract Research & Development Services (CRO) is the primary driver. The others are contract Manufacturing Services (CDMO) and technology Licensing.
Who are Abzena's main competitors?
Direct peers on record are Piramal Pharma Solutions, AGC Biologics and Bionova Scientific. Broad incumbents are FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Catalent (now part of Novo Holdings), Lonza Biologics, Thermo Fisher Scientific (Patheon / Brammer Bio) and WuXi Biologics. Heidelberg Pharma is listed as an emerging player.
Does Abzena have an API?
No public API is recorded for Abzena.
What industry is Abzena in?
Abzena's product category is Biologics and Bioconjugate CDMO/CRO Services. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325412 and its SIC code is 2834.